STEMINENT BIOTHERAPEUTICS, INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 TWD | 0.00% |
|
-0.66% | 0.00% |
| Current month | -10.45% | ||
| 1 month | -6.25% |
| 1 week | -0.66% | ||
| Current month | -10.45% | ||
| 1 month | -6.25% |
1 week
29.00
30.40
1 month
29.0033.55
Current year
28.5553.00
1 year
28.5553.00
3 years
28.5553.00
5 years
28.5553.00
10 years
28.5553.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ling Mei Wang
CEO | Chief Executive Officer | - | 18-11-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Hung Yeh
BRD | Director/Board Member | 52 | 21-12-07 |
Cheng Chi Chiang
BRD | Director/Board Member | - | 20-09-14 |
Ling Mei Wang
CEO | Chief Executive Officer | - | 18-11-25 |
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 51.99M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +36.95% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- 7729 Stock
